Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radiation therapy + temozolomide + NeuroBlate System
- Development stage
- Unknown
- Lead developer
- Monteris Medical
- Modality
- Small Molecules
- Administration
- Oral, Intracranial
01
Overview
This multimodal treatment regimen is being evaluated for the management of newly diagnosed glioblastoma. It combines Laser Interstitial Thermal Therapy (LITT), delivered via Monteris Medical's NeuroBlate System, with the established standard-of-care chemoradiation protocol. The NeuroBlate System is an MRI-guided, robotically-controlled laser ablation tool that allows for the minimally invasive destruction of brain tumor tissue through thermal energy. Following the LITT procedure, patients receive standard-of-care radiation therapy and temozolomide, an oral alkylating chemotherapy agent. This combination is currently being studied in the FLAG clinical trial to determine if the addition of minimally invasive thermal ablation to standard chemoradiation improves clinical outcomes and survival for patients with aggressive primary brain tumors.
- Brand names
- NeuroBlate SystemTemodar
- Other names
- Laser Interstitial Thermal Therapy + radiation therapy + temozolomideLITT + radiation therapy + temozolomideNeuroBlate System + radiation therapy + temozolomide
02
Targets
DNA
Beyond the preview
Go deeper on radiation therapy + temozolomide + NeuroBlate System.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radiation therapy + temozolomide + NeuroBlate System.